A decade ago, many states and metropolitan areas saw bio as their tickets to the future. The gambit didn’t work out for most of them (for my assessment of Phoenix’s effort, you can read here and here). Seattle was fortunate to have an established cluster, which was ranked No. 5 nationally in an influential 2004 report by the Milken Institute. How are we doing now? Hanging on, barely. A new report by Jones Lang LaSalle has Seattle as the nation’s tenth largest “established” bio cluster. The leaders: Boston, San Diego, the Bay Area, Raleigh-Durham, Philadelphia, D.C, New York, Los Angeles and — a newcomer to the list — Minneapolis. Among the “emerging” clusters are Westchester/New Haven, Conn., Chicago, Denver, Cleveland-Columbis-Cincinnati and Salt Lake City.
The report states:
Seattle has one of the fastest growing life sciences markets in the nation and has become one of the core cancer research markets in the nation. Puget Sound’s life sciences is comprised of nearly 1,000 firms employing more than 22,000 directly in the industry, with an additional 191,000 people employed in the hospitals and the medical field. One of the distinguishing features of the Seattle-area life sciences market is that very little manufacturing is done in the region. Nearly all Puget Sound-area life sciences industry activities are based on research and development. Unlike areas with a strong concentration of life sciences manufacturing jobs, when a growing Puget Sound company is purchased by a larger company, the frequent trend has been the employees and the companies to remain intact and local to Seattle. This is the case with many companies like Zymogenetics, which was acquired by Bristol-Myers Squibb in 2010; Blue Heron, which was acquired by OriGene Technologies in 2010; and Sonosite, which is being acquired by Fujifilm.